– USA, CA – Spiral Therapeutics, Inc., a clinical-stage company focused on delivering therapies for the appointments of Dr. Tony Adamis (M.D.) and Fred Guerard (Pharm.D.) to its Board of Directors, effective immediately.
“We are thrilled to welcome Tony and Fred, two exceptional leaders in ophthalmology and medicine, to the Spiral Therapeutics team. Their profound strategic and transformational start-up experience, including Tony’s track record of driving key innovations in medicine and Fred’s profound understanding of ophthalmology and otology, make them invaluable assets to our mission. We are confident that they will help guide Spiral’s ultimate goal of addressing the critical unmet need of hearing loss,” said Executive Chairman, Dr. Eugene de Juan.
About Dr. Antony Adamis
Dr. Adamis, who co-founded EyeBio in 2021 and Eyetech in 2002, previously served as senior vice president of Product Development and Development Innovation at Genentech, a member of The Roche Group. Throughout his career, he has led development programs in multiple therapeutic areas and has overseen 25 U.S. Food and Drug Administration approvals.
About Frederic Guerard
Fred Guerard served as CEO of Graybug Vision and led the planning and successful execution of the company’s IPO in September 2020. Before Graybug, Mr. Guerard spent twenty years of his career at Novartis and Alcon, where he led the Worldwide ophthalmology and otology franchises.
About Spiral Therapeutics
Spiral Therapeutics is a clinical-stage company that delivers therapies for inner ear disorders. Spiral’s novel drug delivery platform allows for minimally invasive, precise, and durable exposure of drugs to the cochlea. Spiral is advancing a therapeutic pipeline focusing on hearing loss and balance disorders. Spiral’s lead program, SPT-2101, is a proprietary sustained-release steroid formulation for treating inner ear inflammation.
For more information: https://www.spiraltx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.